Search

Your search keyword '"V. Lico"' showing total 3 results
Start Over Author "V. Lico"
3 results on '"V. Lico"'

1. Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008–2019)

Author

Gregor Sersa, Christian Kunte, V. Lico, Antonio Orlando, Giulia Bertino, G. Moir, D. Mowatt, E. M. Grischke, J. McCaul, A. D. MacKenzie Ross, Matteo Mascherini, A.J.P. Clover, Falk G. Bechara, Hadrian Schepler, V. Seccia, Tobian Muir, L.G. Campana, G. Pecorari, J. Odili, R. Pritchard Jones, Roberto Giorgione, Julie Gehl, Pietro Curatolo, F. de Terlizzi, Erika Kis, P. Matteucci, Brian Bisase, Matteo Brizio, and Shramana Banerjee

Subjects
Adult, Male, 0301 basic medicine, Cancer Research, Electrochemotherapy, Skin Neoplasms, Databases, Factual, Subgroup analysis, computer.software_genre, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Humans, Medicine, Basal cell carcinoma, Prospective Studies, Kaposi's sarcoma, Aged, Aged, 80 and over, Database, business.industry, Melanoma, Middle Aged, medicine.disease, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Female, Sarcoma, business, computer, Progressive disease
Abstract

Electrochemotherapy (ECT) is a treatment for both primary and secondary cutaneous tumours. The international Network for sharing practices on ECT group investigates treatment outcomes after ECT using a common database with defined parameters.Twenty-eight centres across Europe prospectively uploaded data over an 11-year period. Response rates were investigated in relation to primary diagnosis, tumour size, choice of electrode type, route of bleomycin administration, electrical parameters recorded and previous irradiation in the treated field.Nine hundred eighty-seven patients, with 2482 tumour lesions were included in analysis. The overall response (OR) rate was 85% (complete response [CR]: 70%, partial response rate: 15%, stable disease: 11%, and progressive disease: 2%). For different histologies, OR and CR rates for metastases of malignant melanoma were 82% and 64%, basal cell carcinoma were 96% and 85%, breast cancer metastases were 77% and 62%, squamous cell carcinoma were 80% and 63% as well as Kaposi's sarcoma were 98% and 91%, respectively. Variance was demonstrated across histotypes (p 0.0001) and in accordance with size of lesion treated (dichotomised at diameter of 3 cm (p 0.0001). Hexagonal electrodes were generally used for larger tumours, but for tumours up to 3 cm, linear array electrodes provided better tumour control than hexagonal electrodes (80%:74%, p 0.003). For tumours more than 2 cm, intravenous administration was superior to intratumoural (IT) administration (p 0.05). Current recorded varied across tumour histologies and size but did not influence response rate. In previously irradiated areas, responses were selectively lower for IT administration.These cumulative data endorse efficiency of ECT across a broad range of histotypes. Analysis of 2482 lesions details subgroup analysis on treatment response informing future treatment choices.

Published
2020
Full Text
View/download PDF

2. Outcomes of older adults aged 90 and over with cutaneous malignancies after electrochemotherapy with bleomycin: A matched cohort analysis from the InspECT registry.

Author

Sersa G, Mascherini M, Di Prata C, Odili J, de Terlizzi F, McKenzie GAG, Clover AJP, Bertino G, Spina R, Groselj A, Cappellesso R, Gehl J, Bisase B, Curatolo P, Kis E, Lico V, Muir T, Orlando A, Quaglino P, Matteucci P, Valpione S, and Campana LG

Subjects
Adult, Age Factors, Aged, Aged, 80 and over, Anesthesia, Local, Antibiotics, Antineoplastic adverse effects, Bleomycin adverse effects, Female, Humans, Hyperpigmentation chemically induced, Male, Matched-Pair Analysis, Middle Aged, Neoplasm Recurrence, Local pathology, Pain etiology, Patient Reported Outcome Measures, Registries, Response Evaluation Criteria in Solid Tumors, Skin Neoplasms pathology, Skin Neoplasms secondary, Skin Ulcer chemically induced, Survival Rate, Tumor Burden, Young Adult, Antibiotics, Antineoplastic therapeutic use, Bleomycin therapeutic use, Electrochemotherapy adverse effects, Neoplasm Recurrence, Local drug therapy, Skin Neoplasms drug therapy
Abstract

Background: With extending life expectancy, more people are diagnosed with cutaneous malignancies at advanced ages and are offered nonsurgical treatment. We assessed outcomes of the oldest-old adults after electrochemotherapy (ECT)., Methods: The International Network for Sharing Practices of ECT (InspECT) registry was queried for adults aged ≥90 years (ys) with skin cancers/cutaneous metastases of any histotype who underwent bleomycin-ECT (2006-2019). These were subanalysed with patients aged <90 ys after matching 1:2 for tumor location, number, size, histotype, and previous treatments. We assessed ECT modalities, toxicity (CTCAE), response (RECIST), and patient perception (EQ-5D)., Results: Sixty-one patients represented the study cohort (median 92 ys, range 92-104), 122 the control group (median 77 ys, range 23-89). Among the oldest-old, 44 patients (72%) had primary/recurrent skin cancers, 17 (28%) cutaneous metastases. Median tumour size was 15 mm (range, 5-450). The oldest-old adults underwent ECT mainly under local/regional anaesthesia (59% vs 39% p = .012). We observed no differences regarding dose and route of chemotherapy (intravenous vs intratumoral, p = .308), electrode geometry (linear vs hexagonal, p = .172) and procedural duration (18 vs 21 min, p = .378). Complete response (57.4 [95%-CI 44.1%-70.0%] vs 64.7% [95%-CI 55.6%-73.2%], p = .222) and 1-year local control (76.7% vs 81.7, p = .092) rates were comparable. Pain and skin hyperpigmentation were mild in both groups. Skin ulceration persisted longer in the oldest-old patients (4.4 vs 2.4 months, p = .008)., Conclusions: The oldest-old adults with cutaneous malignancies undergo ECT most commonly under local/regional anaesthesia with safety profiles and clinical effectiveness similar to their younger counterparts, except in case of ulcerated tumors., Competing Interests: Declaration of competing interest GS, MM, JO, JG, GB, BB, PC, EK, VL, TM, AO, RPJ, PQ, JPC, PM, and LGC received travel grants from IGEA S.p.A. (Carpi, Italy) to attend the annual InspECT meeting. FdT is IGEA S.p.A. employee. IGEA S.p.A. hosts the InspECT database, which is administered by an independent board; IGEA did not take part in study design, data collection and interpretation, and manuscript preparation. GAGM, CDP, RS, RC, and SV have no competing interests to declare., (Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.)

Published
2021
Full Text
View/download PDF

3. Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms.

Author

Obazee O, Capurso G, Tavano F, Archibugi L, De Bonis A, Greenhalf W, Key T, Pasquali C, Milanetto AC, Hackert T, Fogar P, Lico V, Dervenis C, Lawlor RT, Landoni L, Gazouli M, Zambon CF, Funel N, Strobel O, Jamroziak K, Cantu C, Malecka-Panas E, Landi S, Neoptolemos JP, Basso D, Talar-Wojnarowska R, Rinzivillo M, Andriulli A, Canzian F, and Campa D

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results